ABCC3在癌症耐药性中的意义：我们能否将其用作治疗靶点？
The implications of ABCC3 in cancer drug resistance: can we use it as a therapeutic target?
作者信息
Ramírez-Cosmes Adriana, Reyes-Jiménez Edilburga, Zertuche-Martínez Cecilia, Hernández-Hernández Carlos A, García-Román Rebeca, Romero-Díaz Roberto I, Manuel-Martínez Adán E, Elizarrarás-Rivas Jesús, Vásquez-Garzón Verónica R
机构信息
Laboratorio Fibrosis y Cáncer, Facultad de Medicina y Cirugía, Universidad Autónoma "Benito Juárez" de Oaxaca Oaxaca, Oax, México.
Hospital Regional Presidente Juárez ISSSTE Oaxaca Oaxaca, Oax, México.
出版信息
Am J Cancer Res. 2021 Sep 15;11(9):4127-4140. eCollection 2021.
Drug resistance is one of the main causes of chemotherapy failure. Although several factors are involved in cancer drug resistant, the exporter pumps overexpression that mediates the drugs flow to outside the cells and reduces both the drugs intracellular concentration and effectiveness, has been one of the most important challenges. Overexpression of ABCC3, a member of the ABCC subfamily, has been strongly associated to the resistance to multiple drugs. ABCC3 has been found highly expressed in different types of cancers and is associated with poor prognosis and resistance to treatments. In this review, we summarize the molecular mechanisms involved in cancer drug resistance and discuss the current knowledge about the structure, function and role of ABCC3 in drug resistance, as well as, the expression status of ABCC3 in different types of cancer. We also provide evidences that place ABCC3 as a potential therapeutic target for improving the cancer treatment by focusing on the need of developing more effective cancer therapies to target ABCC3 in translational researches.
耐药性是化疗失败的主要原因之一。尽管癌症耐药涉及多个因素，但介导药物外流至细胞外从而降低药物细胞内浓度和疗效的外排泵过度表达，一直是最重要的挑战之一。ABCC亚家族成员ABCC3的过度表达与多种药物耐药性密切相关。已发现ABCC3在不同类型癌症中高度表达，并与预后不良及治疗耐药相关。在本综述中，我们总结了癌症耐药所涉及的分子机制，并讨论了目前关于ABCC3在耐药中的结构、功能和作用的认识，以及ABCC3在不同类型癌症中的表达情况。我们还通过关注在转化研究中开发更有效的靶向ABCC3癌症治疗方法的需求，提供证据表明ABCC3是改善癌症治疗的潜在治疗靶点。
Zotero 插件